G

Gubra A/S
CSE:GUBRA

Watchlist Manager
Gubra A/S
CSE:GUBRA
Watchlist
Price: 533 DKK -0.19% Market Closed
Market Cap: 8.7B DKK

Gubra A/S
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Gubra A/S
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
G
Gubra A/S
CSE:GUBRA
Free Cash Flow
-kr27.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chemometec A/S
CSE:CHEMM
Free Cash Flow
kr142.7m
CAGR 3-Years
6%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Gubra A/S
Glance View

Nestled in the scientific hub of Denmark, Gubra A/S has carved a niche for itself in the dynamic world of biotechnology. Since its inception in 2008, the company has anchored its reputation on its pioneering work in preclinical contract research. At its core, Gubra specializes in providing pivotal insights and support for pharmaceutical giants working on metabolic and fibrotic diseases. Through meticulous study and advanced technological frameworks, such as their proprietary imaging platforms and tailored animal models, Gubra delivers essential data that propels drug discovery forward. Their B2B model thrives on collaborating with major pharmaceutical firms, assisting them in navigating the complex maze of early-stage drug development. Beyond its contract research capabilities, Gubra has also ventured into developing its own proprietary pipeline of peptide-based drug candidates. This dual-strategy approach demonstrates their deft versatility—balancing service-based revenue streams with the potential high returns from successful drug development. While their focus remains predominantly on addressing metabolic ailments like diabetes and obesity, the company's exploration into fibrosis shows a forward-thinking attitude towards expanding their portfolio. By combining cutting-edge research with strategic alliances, Gubra continues to position itself as a vital player in biotech, capturing the synergies between scientific innovation and commercial application.

GUBRA Intrinsic Value
433.83 DKK
Overvaluation 19%
Intrinsic Value
Price
G

See Also

What is Gubra A/S's Free Cash Flow?
Free Cash Flow
-27.1m DKK

Based on the financial report for Dec 31, 2024, Gubra A/S's Free Cash Flow amounts to -27.1m DKK.

What is Gubra A/S's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
55%

Over the last year, the Free Cash Flow growth was 55%.

Back to Top